Registry of Lobbyists
Version 3 of 5 (2002-01-21 to 2003-03-04) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
SANOFI-SYNTHELABO CANADA INC.
15 ALLSTATE PARKWAY MARKHAM, ON L3R 5B4 Canada |
| Telephone number: | 905-513-4360 |
| Fax number: | 905-513-4580 |
| Responsible officer name and position during the period of this registration: | BETTY ANN RAFUSE, VICE-PRESIDENT, REGULATORY AFFAIRS AND QUALITY AS |
| Description of activities: | SANOFI-SYNTHELABO CANADA IS A CANADIAN PHARMACEUTICAL AFFILIATE WITH ITS CORPORATE HEAD OFFICE IN PARIS, FRANCE. NEW YORK CITY IS THE HOME BASE FOR OUR NORTH AMERICAN OPERATION. IN CANADA, WE MARKET AND DISTRIBUTE ETHICAL PHARMACEUTICAL PRODUCTS. THE AREAS OF CURRENT AND FUTURE THERAPEUTIC INTERESTS INCLUDE CARDIOVASCULAR MEDICINE, ONCOLOGY AND CENTRAL NERVOUS SYSTEM DISORDERS. |
| Parent: | The corporation is not a subsidiary of any other parent corporations. |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Canadian International Development Agency (CIDA), Environment Canada, Federal Environmental Assessment Review Office (FEARO), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB) |
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format |
| Subject Matter: Areas of Concern: | Consumer Issues, Health, Industry, Intellectual Property, International Trade, Science and Technology |
| Subject Matter: Particulars: | SANOFI-SYNTHELABO CANADA INC. INTERACTS WITH GOVERNMENT AGENCIES ON A REGULAR BASIS AS REQUIRED IN ORDER TO SECURE AUTHORIZATION UNDER THE FOOD AND DRUG ACT AND ITS REGULATIONS, FOR (1) CONDUCTING CLINICAL DEVELOPMENTAL PROGRAMS ON POTENTIAL NEW PHARMACEUTICAL PRODUCTS OR EXPANDED INDICATIONS FOR EXISTING PRODUCTS; (2) TO OBTAIN THE APPROVALS NECESSARY FOR THE INTRODUCTION OF NEW PHARMACEUTICAL PRODUCTS OR TO EXPANDED INDICATIONS/REVISED DOSING REGIMENS FOR EXISTING PRODUCTS; (3) FOR THE PURPOSES OF MEETING ITS REGULATORY OBLIGATIONS BY SUBMITTING PRODUCT SAFETY REPORTS. THE COMPANY ALSO DISTRIBUTES PRODUCTS COVERED UNDER THE PATENT ACT AND NARCOTICS ACT AND THEIR REGULATIONS AND DEALS WITH THE GOVERNMENT ORGANIZATIONS WHO HAVE JURISDICTION IN THESE AREAS ON A REGULAR BASIS. THE COMPANY OCCASIONALLY MAKE REPRESENTATIONS ON THE TAXATION TREATMENT OF SCIENTIFIC RESEARCH AND EXPERIMENTAL DEVELOPMENT. THE COMPANY HAS HISTORICALLY SUPPORTED CIDA PROGRAMS THROUGH THE DONATION OF PRODUCTS. |